Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis
Identifieur interne : 002462 ( Main/Exploration ); précédent : 002461; suivant : 002463Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis
Auteurs : David M. Aboulafia [États-Unis] ; Denise Bundow ; Kenneth Wilske ; Ulrike I. OcasSource :
- Mayo Clinic Proceedings [ 0025-6196 ] ; 2000.
English descriptors
- Teeft :
- Acad dermatol, Active antiretroviral therapy, Arthritis, Arthritis rheum, Bacterial infections, Blood cultures, Cell count, Clin, Clinical course, Congestive heart failure, Distal phalanges, Erythrocyte sedimentation rate, Etanercept, Extensive psoriatic plaques, Fusion protein, Fusion protein enbreltm, Human immunodeficiency virus infection, Immunodeficiency, Immunodeficiency syndrome, Important role, Interphalangeal, Joint destruction, Joint inflammation, Leukocyte count, Mayo, Mayo clin proc, Mayo clinic proceedings, Other spondyloarthropathies, Profound disability, Psoriasis, Psoriatic, Psoriatic arthritis, Psoriatic arthropathy, Receptor, Reiter syndrome, Rheum, Rheumatoid, Rheumatoid arthritis, Severe periarticular bone demineralization, Syndrome, Synovial fluid, Thalidomide, Topical corticosteroids, Tumor necrosis factor, Tumor necrosis factor receptor, Viral, Viral load, Weight loss.
Abstract
Etanercept may play an important role in modulating the inflammatory activity and progression of human immunodeficiency virus (HIV)-associated psoriasis and psoriatic arthritis. We report the case of a 45-year-old homosexual man with a CD4 cell count of less than 0.05 109/L and an HIV viral load of 4200 copies/mL (while receiving highly active antiretroviral therapy) who developed extensive psoriatic plaques, 4.5-kg weight loss, onychodystrophy, and psoriatic arthropathy with severe periarticular bone demineralization. The arthritis progressed despite the use of several disease-modifying medications, including corticosteroids, hydroxy chloroquine, and minocycline. Because of uncontrolled, progressive, and disabling arthritis and resulting profound disability, he was treated with etanercept. Within 3 weeks, his psoriasis had improved dramatically and his joint inflammation had stabilized. For the next 4 months, immunologic and viral parameters remained stable, but his clinical course was complicated by frequent polymicrobial infections. Etanercept was thus discontinued despite continued improvements in his psoriasis, psoriatic arthritis, and functional status. While both cutaneous and joint manifestations of psoriasis improved dramatically, the experience with this patient dictates that caution and careful follow-up must be exercised when prescribing etanercept in the setting of HIV infection.
Url:
DOI: 10.4065/75.10.1093
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000639
- to stream Istex, to step Curation: 000639
- to stream Istex, to step Checkpoint: 001279
- to stream Main, to step Merge: 002490
- to stream Main, to step Curation: 002462
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis</title><author><name sortKey="Aboulafia, David M" sort="Aboulafia, David M" uniqKey="Aboulafia D" first="David M." last="Aboulafia">David M. Aboulafia</name></author><author><name sortKey="Bundow, Denise" sort="Bundow, Denise" uniqKey="Bundow D" first="Denise" last="Bundow">Denise Bundow</name></author><author><name sortKey="Wilske, Kenneth" sort="Wilske, Kenneth" uniqKey="Wilske K" first="Kenneth" last="Wilske">Kenneth Wilske</name></author><author><name sortKey="Ocas, Ulrike I" sort="Ocas, Ulrike I" uniqKey="Ocas U" first="Ulrike I." last="Ocas">Ulrike I. Ocas</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8EE879A08EC4140672D806A9D99A40683D2E0A75</idno><date when="2000" year="2000">2000</date><idno type="doi">10.4065/75.10.1093</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-C4L9CBNT-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000639</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000639</idno><idno type="wicri:Area/Istex/Curation">000639</idno><idno type="wicri:Area/Istex/Checkpoint">001279</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001279</idno><idno type="wicri:doubleKey">0025-6196:2000:Aboulafia D:etanercept:for:the</idno><idno type="wicri:Area/Main/Merge">002490</idno><idno type="wicri:Area/Main/Curation">002462</idno><idno type="wicri:Area/Main/Exploration">002462</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis</title><author><name sortKey="Aboulafia, David M" sort="Aboulafia, David M" uniqKey="Aboulafia D" first="David M." last="Aboulafia">David M. Aboulafia</name><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Address reprint requests and correspondence to David M. Aboulafia, MD, Division of Hematology/Oncology, Virginia Mason Clinic, 1100 Ninth Ave (H14-HEM), Seattle</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Bundow, Denise" sort="Bundow, Denise" uniqKey="Bundow D" first="Denise" last="Bundow">Denise Bundow</name><affiliation><wicri:noCountry code="subField">Wash</wicri:noCountry></affiliation></author><author><name sortKey="Wilske, Kenneth" sort="Wilske, Kenneth" uniqKey="Wilske K" first="Kenneth" last="Wilske">Kenneth Wilske</name><affiliation><wicri:noCountry code="subField">Wash</wicri:noCountry></affiliation></author><author><name sortKey="Ocas, Ulrike I" sort="Ocas, Ulrike I" uniqKey="Ocas U" first="Ulrike I." last="Ocas">Ulrike I. Ocas</name><affiliation><wicri:noCountry code="subField">Wash</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Mayo Clinic Proceedings</title><title level="j" type="abbrev">JMCP</title><idno type="ISSN">0025-6196</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">75</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1093">1093</biblScope><biblScope unit="page" to="1098">1098</biblScope></imprint><idno type="ISSN">0025-6196</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0025-6196</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad dermatol</term><term>Active antiretroviral therapy</term><term>Arthritis</term><term>Arthritis rheum</term><term>Bacterial infections</term><term>Blood cultures</term><term>Cell count</term><term>Clin</term><term>Clinical course</term><term>Congestive heart failure</term><term>Distal phalanges</term><term>Erythrocyte sedimentation rate</term><term>Etanercept</term><term>Extensive psoriatic plaques</term><term>Fusion protein</term><term>Fusion protein enbreltm</term><term>Human immunodeficiency virus infection</term><term>Immunodeficiency</term><term>Immunodeficiency syndrome</term><term>Important role</term><term>Interphalangeal</term><term>Joint destruction</term><term>Joint inflammation</term><term>Leukocyte count</term><term>Mayo</term><term>Mayo clin proc</term><term>Mayo clinic proceedings</term><term>Other spondyloarthropathies</term><term>Profound disability</term><term>Psoriasis</term><term>Psoriatic</term><term>Psoriatic arthritis</term><term>Psoriatic arthropathy</term><term>Receptor</term><term>Reiter syndrome</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Severe periarticular bone demineralization</term><term>Syndrome</term><term>Synovial fluid</term><term>Thalidomide</term><term>Topical corticosteroids</term><term>Tumor necrosis factor</term><term>Tumor necrosis factor receptor</term><term>Viral</term><term>Viral load</term><term>Weight loss</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Etanercept may play an important role in modulating the inflammatory activity and progression of human immunodeficiency virus (HIV)-associated psoriasis and psoriatic arthritis. We report the case of a 45-year-old homosexual man with a CD4 cell count of less than 0.05 109/L and an HIV viral load of 4200 copies/mL (while receiving highly active antiretroviral therapy) who developed extensive psoriatic plaques, 4.5-kg weight loss, onychodystrophy, and psoriatic arthropathy with severe periarticular bone demineralization. The arthritis progressed despite the use of several disease-modifying medications, including corticosteroids, hydroxy chloroquine, and minocycline. Because of uncontrolled, progressive, and disabling arthritis and resulting profound disability, he was treated with etanercept. Within 3 weeks, his psoriasis had improved dramatically and his joint inflammation had stabilized. For the next 4 months, immunologic and viral parameters remained stable, but his clinical course was complicated by frequent polymicrobial infections. Etanercept was thus discontinued despite continued improvements in his psoriasis, psoriatic arthritis, and functional status. While both cutaneous and joint manifestations of psoriasis improved dramatically, the experience with this patient dictates that caution and careful follow-up must be exercised when prescribing etanercept in the setting of HIV infection.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Washington (État)</li></region></list><tree><noCountry><name sortKey="Bundow, Denise" sort="Bundow, Denise" uniqKey="Bundow D" first="Denise" last="Bundow">Denise Bundow</name><name sortKey="Ocas, Ulrike I" sort="Ocas, Ulrike I" uniqKey="Ocas U" first="Ulrike I." last="Ocas">Ulrike I. Ocas</name><name sortKey="Wilske, Kenneth" sort="Wilske, Kenneth" uniqKey="Wilske K" first="Kenneth" last="Wilske">Kenneth Wilske</name></noCountry><country name="États-Unis"><region name="Washington (État)"><name sortKey="Aboulafia, David M" sort="Aboulafia, David M" uniqKey="Aboulafia D" first="David M." last="Aboulafia">David M. Aboulafia</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002462 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002462 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8EE879A08EC4140672D806A9D99A40683D2E0A75
|texte= Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |